Connecticut Begins Recreational Marijuana Sales at Approved Dispensaries

Jan.11.2023
Connecticut Begins Recreational Marijuana Sales at Approved Dispensaries
Connecticut legalizes recreational marijuana, with up to 40 pharmacies and other businesses expected to open by year-end.

Special Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not make recommendations for any specific product nor does it comment on any domestic policies.


The legality of the product mentioned in the article is only applicable in the local overseas area. Domestic readers should take note and strictly abide by Chinese laws and regulations.


3. This article is not intended as an investment or consumption advice.


This article is prohibited for minors to read.


On January 10th, 2023, recreational marijuana sales opened for adults 21 years and older in Connecticut. The sales began at the state's seven existing medical marijuana dispensaries. This came less than two years after Governor Ned Lamont signed legislation making Connecticut a legal marijuana state.


It is expected that up to 40 pharmacies and dozens of other cannabis-related businesses will ultimately open in Connecticut by the end of this year.


Today is historic, but the real story is about the benefits of changing lives and communities," said Adam Wood, president of the Connecticut Cannabis Industry Association in a statement. He estimates that this new industry will create over 10,000 job opportunities in the coming years and generate billions of dollars in new revenue, which will help to benefit communities most affected by the war on drugs.


On Tuesday, Democratic lawmaker Ramonte stated that one of the goals of legislation legalizing recreational marijuana is to create a regulated and safer product for consumers. Another aspect of the law allows for the expungement of convictions for low-level marijuana crimes, many of which are automatically cleared. Officials report that since the start of the new year, nearly 44,000 such convictions have been expunged.


Today marks a turning point in the unjust consequences of the war on drugs, as the most noteworthy development is the emergence of an unregulated underground market for legal substitutes to marijuana," said Lamont in a statement.


On January 10th at 10am, the sale of recreational marijuana was allowed to begin. State-approved shops in Branford, Meriden, Montville, New Haven, Newington, Stamford, and Willimantic are expected to open to the public on the first day. Two additional approved pharmacies in Danbury and Torrington will open later.


On Tuesday, January 10, 2023, customers lined up outside The Botanist in Montville, Connecticut to purchase cannabis products, marking the first day of recreational cannabis sales in the state. Seven existing medical cannabis locations have been granted mixed licenses to sell recreational cannabis to adults aged 21 and over, and are open to the public. It is expected that up to 40 dispensaries will open statewide by the end of the year.


In Monteville, local state legislators and the mayor attended the ribbon-cutting ceremony of The Botanist. Prior to the start of recreational sales, a steady stream of medical marijuana patients stopped by to pick up their orders. Staff folded free t-shirts inside heated tents, ready to assist customers with placing orders at the sales kiosks.


Lynn Goldstein, a 60-year-old from Norwich, was the first customer in line at the Montreal dispensary. She stated that she has been using medical marijuana for chronic pain since 2011 and is pleased that recreational sales are now legal, but also has some concerns.


I am genuinely concerned about young people because they do not know how to handle themselves and are more likely to drink and drive, which makes it difficult for police to establish the facts," she said.


Goldstein added that she didn't intend to be the first person in line, but she was glad she was. She received a goodie bag that included a $250 vaporizer.


Around 20 people were seen lining up before the opening of Fine Fettle pharmacy in Willimantic. The pharmacy has implemented a policy requiring customers to order online and arrive at the store at a designated time to avoid long queues.


On January 10, 2023, customers were seen lining up outside Fine Fettle marijuana dispensary in Willimantic, Connecticut, waiting for the legal sale of recreational marijuana in the state. It is estimated that by the end of this year, up to 40 dispensaries and dozens of other marijuana-related businesses will ultimately open in Connecticut.


Samuel Gabbey, a 32-year-old parcel delivery operations manager from Mansfield, has been waiting for this day for many years. He recommends that people should instead buy from legal stores to avoid purchasing from strangers and alleviate concerns over unknown substances added to marijuana.


Finally, there will come a day when we can all come here, get what we want, and go home without worrying about the police or anything," he said. "So today is a good day for the people of Connecticut.


It is unclear if the novelty of marijuana legalization will have an impact on consumers in Connecticut, given that it began retail sales last year in the neighboring state of Massachusetts and more recently in Rhode Island and New York.


In the past decade, 21 states have legalized adult recreational marijuana use, despite it remaining illegal under federal law. Since last November when Maryland and Missouri voters approved legalization, marijuana advocates have been pushing similar efforts in other parts of the United States, including Ohio and Oklahoma.


According to data from the National Conference of State Legislatures, as of February 3, 2022, 37 states, three territories, and the District of Columbia allow the use of marijuana products for medical purposes.


On Tuesday, a "hybrid" medical and recreational marijuana retail store in Connecticut prepared for a large crowd.


Kate Nelson, Senior Vice President of Acreage Holdings in the Midwest and Northwest regions, which owns the Botanist brand, stated that the Montville factory receives around 200 to 300 medical marijuana clients per day. She predicted that sales would increase by 150% in the first week of recreational sales; however, she acknowledges that this growth may level off over time.


The company's second location in Connecticut will be located in Danbury and is expected to open in the coming weeks after final approval from local authorities.


I believe that even before the launch of the 40 operators, we will begin to see less excitement about new developments and more focus on how the current state will evolve," said Nielsen. "There are other adult-use states near our region, so this will really be a priority for us, especially in Connecticut, to ensure that the adult-use program has the products it needs and that we can support the industry... to ensure Connecticut is prepared for competition in the market.


The initial sales limit for marijuana in Connecticut will be set at a quarter of an ounce (7 grams) of marijuana flower or an equivalent amount, in order to ensure adequate supply for medical marijuana patients. Customers may purchase different items together to make up for the quarter of an ounce limit. The state's Department of Consumer Protection plans to closely monitor retail sales and manufacturing supply in order to determine when this amount can be increased in the future.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden is expected to oppose a European Union proposal to raise minimum tobacco excise duties, Law360 reported on October 26, 2026, citing an EU official. A provisional Council agenda dated October 23 confirms that the tobacco taxation package is scheduled for discussion at the November 9 finance ministers' meeting, where member states will seek a general approach. The proposed reforms would raise minimum taxes on conventional tobacco products and establish EU-wide excise rules for vaping liquids, heated tobacco and nicotine pouches. Sweden supports harmonising tobacco taxation rules but objects to requiring nicotine pouches to bear the same minimum tax burden as certain smoking tobacco products. As EU indirect tax legislation requires unanimous Council approval, Swedish opposition could block the proposal in its current form.
Regulations
Oct.29
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08